Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Schweiz
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Andere Sprachen
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über ROCHE HOLDING AG
15.10.ROCHE : la FDA homologue Tecentriq pour certains cancers du poumon
15.10.ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E..
15.10.ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea..
15.10.PRESS RELEASE : US FDA approves Roche's Tecentriq -2-
15.10.PRESS RELEASE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people..
15.10.GENENTECH : FDA Approves Tecentriq as Adjuvant Treatment for Certain Lung Cancer Patients
15.10.Investir dans la stabilité
15.10.ROCHE : a conclu un accord avec PathAI
15.10.Roche s'associe à Pathai dans l'imagerie médicale
15.10.ROCHE : Joins PathAI to Develop AI-Based Image Analysis Workflow for Pathologists
15.10.ROCHE : autorisation à durée limitée de Gavreto par Swissmedic
15.10.ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology..
15.10.PRESS RELEASE : Roche announces PathAI collaboration for artificial intelligence-based dig..
14.10.ROCHE : U.S. FDA advisers to review Merck's oral COVID-19 drug next month
14.10.ROCHE : examen prioritaire de la FDA pour REGEN-COV
14.10.ROCHE : le Regen Cov jugé prioritaire aux USA en prévention de la Covid
14.10.ROCHE : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatmen..
14.10.ROCHE : résultats encourageants dans les troubles NMOSD
14.10.ROCHE : Scores Wins In Blood Cancer, Rare Nervous Disorder Therapeutic Areas
14.10.ROCHE : Invitation to Roche's Virtual Event "Digitalization along the value chain"
14.10.ROCHE : a reçu l'approbation de l'EMA pour Gazyvaro
14.10.ROCHE : Rare Central Nervous System Disease Therapy Reduces Relapses In Patients
14.10.Le Gazyvaro de Roche autorisé en Europe avec une perfusion plus courte
14.10.ROCHE : Wins EU Nod For Shorter Gazyvaro Infusion Time in Follicular Lymphoma Patients
14.10.ROCHE : New four-year data show Roche's ENSPRYNG significantly reduces debilitating relaps..
14.10.PRESS RELEASE : New four-year data show Roche's -2-
14.10.PRESS RELEASE : New four-year data show Roche's ENSPRYNG significantly reduces debilitatin..
14.10.Roche Holding Ag Announces New Longer-Term Efficacy and Safety Data for ENSPRYNG
14.10.ROCHE : New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduce..
14.10.ROCHE : Gazyvaro shorter 90-minute infusion time approved in Europe for people with previo..
14.10.PRESS RELEASE : Roche's Gazyvaro shorter 90-minute -2-
14.10.PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..
14.10.Roche’s Gazyvaro Shorter 90-Minute Infusion Time Gets Approval in Europe for People wit..
13.10.SYNAIRGEN : Appoints Chugai Pharma Executive as Chief Regulatory Officer
13.10.ROCHE : données positives dans les scléroses en plaques
13.10.REMINDER : Invitation to Roche's 3rd Quarter Sales 2021 Webinar
13.10.ROCHE : Long-Term Data on Multiple Sclerosis Therapy Affirms Early, Ongoing Treatment Bene..
13.10.ROCHE : New Data up to 8-Years for Genentech's Ocrevus (ocrelizumab) Show Early and Ongoin..
13.10.ROCHE : Data up to 8-years for Roche's OCREVUS (ocrelizumab) show early and ongoing treatm..
13.10.PRESS RELEASE : Data up to 8-years for Roche's -2-
13.10.PRESS RELEASE : Data up to 8-years for Roche's OCREVUS (ocrelizumab) show early and ongoin..
13.10.Roche Announces New Long-Term Data That Reinforce the Benefit of Early Initiation and O..
12.10.CombiGene Shares More Than Double on $328.5 Million Epilepsy Therapy Deal
12.10.CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene t..
12.10.ROCHE : Japanese Unit Seeks Regulatory Nod For Additional COVID-19 Monoclonal Antibody Ind..
11.10.ROCHE : Chugai files for additional indications of Ronapreve for prophylaxis and treatment..
11.10.GLOBAL MARKETS LIVE : Facebook, Apple, KKR, Adler, Roche...
11.10.ROCHE : European Medicines Agency Reviews COVID-19 Antibody Cocktail Developed by Roche, R..
11.10.ROCHE : l'UE débute la procédure d'examen du médicament Ronapreve contre Covid-19
11.10.EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
11.10.REGENERON PHARMACEUTICALS : EU assesses Regeneron/Roche COVID-19 antibody cocktail for aut..
11.10.BÖRSE MADRID : Resultados a prueba de inflación y escasez
11.10.EN DIRECT DES MARCHES : Carrefour, Ipsen, CGG, Facebook, Apple, Lenovo, Adler, Idorsia...
08.10.Alzheimer-medicijn Roche baanbrekend volgens FDA
08.10.ROCHE : says Alzheimer's therapy gets U.S. breakthrough designation
08.10.ROCHE : statut de 'Breakthrough Therapy' dans Alzheimer
08.10.Roche obtient le statut de percée thérapeutique aux USA pour gantenerumab
08.10.ROCHE : Alzheimer Drug Gets US FDA's Breakthrough Therapy Designation
08.10.ROCHE : says Alzheimer's antibody gets U.S. breakthrough designation
08.10.ROCHE : anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designati..
08.10.GENENTECH : 's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy De..
08.10.Roche's Gantenerumab Gets FDA Breakthrough Therapy Designation for Alzheimer's Disease
07.10.ROCHE : Philippine Drug Regulator OKs Roche-Regeneron's COVID-19 Antibody Cocktail
05.10.ROCHE : nouvelles données pour la sclérose en plaques
05.10.ROCHE : Highlights Long-Term Efficacy Of Neurological Disorder Drugs
05.10.Roche promeut son Ocrevus et l'Enspryng sur le long terme
05.10.GENENTECH : to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryn..
05.10.ROCHE : to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis..
05.10.PRESS RELEASE : Roche to present new data on -3-
05.10.PRESS RELEASE : Roche to present new data on -2-
05.10.PRESS RELEASE : Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in..
04.10.CHUGAI PHARMACEUTICAL : Receives Orphan Drug Designation for Hemlibra in Acquired Hemophil..
04.10.CHOROIDEREMIA PIPELINE : Industry Analysis, Drugs, Pipeline, Treatment and Key Companies b..
02.10.ROCHE : Malaysia in talks to procure Merck's COVID-19 pills
01.10.Merck COVID-19 pill success slams Moderna shares, shakes up healthcare sector
1  2  3  4  5  6  7  8  9  10Weiter
Anstehende Termine für ROCHE HOLDING AG
20.10.21